Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s Why These Four Stocks Are Trending Today

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is trending after the drug company disclosed in a recent 10-Q that it received a subpoena from the Department of Justice related to the way it marketed its medicines. The subpoena specifically requested more documents related to the company’s ‘Good Laboratory Practices in a bioanalytical laboratory’. Pharmaceutical investors have been on edge in recent months as many pharma and biotech stocks have cratered due to concerns of increased government regulation over pricing and other aspects of their operations. Although any sign of a potential government probe is bad news, investors don’t believe Vertex Pharmaceuticals’ issue is serious, as shares are down only modestly so far. Our data shows hedge funds are not overly bullish on Vertex. 45 funds in our database reported stakes in the company worth $1.14 billion, accounting for just 3.80% of its float at the end of June.

Follow Vertex Pharmaceuticals Inc / Ma (NASDAQ:VRTX)
Trade (NASDAQ:VRTX) Now!

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is trending after noted short-seller Andrew Left of Citron Research said in the Wall Street Journal that he doesn’t plan on publishing anything ‘earth-shattering’ on the company on Monday. Left previously published a scathing report on Valeant accusing the company of sending some business through a phantom specialty pharmacy to avoid auditor scrutiny. The report sent Valeant shares into a tailspin. Because of Left’s report and concerns over increased government regulation over drug prices, shares of the company are down by 34% year-to-date and by more than 60% since August.

Despite the poor performance, Bill Ackman of Pershing Square is still a fan, with a holding of 19.47 million shares at the end of June. Ackman thinks Valeant shares could be worth over $400 per share in three years and said that if he had more capital, he would buy even more shares than he already owns.

Follow Valeant Pharmaceuticals International (NYSE:VRX)
Trade (NYSE:VRX) Now!

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.